Dcf Advisers, LLC Nektar Therapeutics Transaction History

Dcf Advisers, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$3.17 - $6.17 $47,550 - $92,550	-15,000 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$4.16 - $13.72 $67,808 - $223,636	-16,300 Reduced 52.08%	15,000 $81,000
Q4 2020 Feb 12, 2021	SELL	$15.77 - $19.03 $7,885 - $9,515	-500 Reduced 1.57%	31,300 $532,000
Q3 2020 Nov 13, 2020	SELL	$16.59 - $24.79 $185,808 - $277,648	-11,200 Reduced 26.05%	31,800 $528,000
Q4 2019 Feb 12, 2020	BUY	$15.87 - $23.12 $682,410 - $994,160	43,000 New	43,000 $928,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $242M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Dcf Advisers, LLC with notifications on news.